Photo of Kashish Gupta

Kashish Gupta

Associate in Public Policy at the Mumbai office of Cyril Amarchand Mangaldas. Kashish can be reached at kashish.g@cyrilshroff.com

Beyond the Advisory - The Legal Framework Governing GLP-1 Drug Advertising

Summary: This article examines the reach of the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954, through the lens of key judicial pronouncements – from the Supreme Court’s ruling in Hamdard Dawakhana upholding the constitutionality of advertising restrictions to the Bombay High Court’s broad reading of Section 4 as a catch-all prohibition against misleading drug advertisements and the Supreme Court’s recent observations in the Patanjali matter. These rulings map the boundaries of what constitutes a prohibited advertisement and identify the penal consequences under the Drugs and Cosmetics Act, 1940 Act and the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954, for non-compliance with the Advisory.

Continue Reading Beyond the Advisory – The Legal Framework Governing GLP-1 Drug Advertising (Part 2)
From Awareness to Advertising: Re-examining the GLP-1 drug boundaries (Part 1)

Summary: Part 1 of this Article examines the CDSCO’s March 2026 Advisory directed at manufacturers, importers and marketing authorisation holders of GLP-1 receptor agonists, reinforcing that regulatory scrutiny of prescription-only medicine promotion will focus on substance over form. It prohibits all advertising — whether direct, surrogate, or influencer-led — that create brand recall among public.

Continue Reading From Awareness to Advertising: Re-examining the GLP-1 drug boundaries (Part 1)